Latest Administration News

Gold Mountain Limited has announced a fully underwritten $1.5 million entitlement offer alongside a $2 million placement to accelerate exploration activities in Brazil and Papua New Guinea. The capital raising, discounted by 40% to recent share prices, is underwritten by major shareholder José Luis Manzano, who may increase his stake to nearly 20%.

Island Pharmaceuticals has submitted a detailed briefing to the FDA aiming to accelerate approval of its antiviral Galidesivir for Marburg virus under the Animal Rule, with feedback expected by November.

Bravura Solutions has appointed Colin Greenhill as its new Group CEO, effective 1 January 2026, following a comprehensive global search. Greenhill brings over 15 years of leadership experience in financial services software, signaling a strategic step forward for the company.

Super Retail Group Limited has updated its dividend details, confirming a fully franked ordinary dividend of AUD 0.34 per share and a special dividend of AUD 0.30 per share, alongside an updated dividend reinvestment plan price of AUD 16.90.

Bod Science Limited has reported a notable profit turnaround for FY2025, driven by medicinal cannabis sales growth, while navigating a complex Deed of Company Arrangement and a proposed backdoor listing with Biortica Agrimed Limited.

XRF Scientific Limited has confirmed its fully franked ordinary dividend for the 2025 financial year and updated details of its Dividend Reinvestment Plan price, offering shareholders a clear view on income and reinvestment options.

Manuka Resources has received a binding debt offer to refinance existing obligations and support the restart of its Wonawinta silver and gold processing plant in early 2026, leveraging current high metal prices.

Metro Finance 2021-1 Trust’s $652 million Class A Notes have been suspended from trading and removed from the ASX Official List following their redemption last November.

Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

The European Medicines Agency has approved continuous bi-monthly dosing of CLINUVEL’s SCENESSE® for adult erythropoietic protoporphyria patients, removing previous annual dose limits and aligning Europe with US treatment standards.

Domino’s Pizza Enterprises has updated its dividend announcement to include a DRP price of AUD 14.26 with a 1% discount, alongside an unfranked dividend of AUD 0.215 per share for the half-year ending June 2025.